Next Phase Newsletter

A venture capital and growth equity firm is actively making investments in life sciences, and will invest as early as Series A and through growth transactions and is currently investing out of their second fund. New Rhein looks to invest between $10-30M per investment. The firm is looking for companies with clinical data and/or commercial products. The firm has a preference for funding companies that are repurposing existing approved technologies for new indications. The firm is willing to invest in therapeutics, medical device and diagnostics companies.

The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication.

The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global leader in life sciences, diagnostics and applied chemical markets providing services, equipment, and support solutions to laboratories worldwide has an Early Stage Partnership Program through which the firm works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit to the firm’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.

The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Bioproduction Instrumentation, Cell & Gene Therapy Tools, Cellular Engineering and Analysis, Genomics, Lab Data Analytics & Informatics, Molecular Diagnostics and Sample Preparation. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.

The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices in the USA has assets under management of $1.6 billion. Since inception, the firm has raised five investment funds. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity.

The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.

The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based out of USA that invests exclusively in the mental health and neurology space. The firm’s biotech segment is interested in companies related to neuroscience and neurotherapeutics. The firm is raising their second fund right now, their first fund closed at over $22M. The firm looks to make Seed and Series A investments in the form of equity or convertible notes with a typical check size ranging from $500K-1.5M. The firm seeks to make investments in North America and Europe.

The firm is open to all 4 sectors as they relate to neurology. The firm is agnostic to subsector and indication with a particular focus on psychiatry and neurodegenerative diseases. The firm is open to pre-clinical and pre-prototype companies and is open to all 3 classes of medical devices with a stronger focus on 510K and PMA.

The firm is open to all types of management teams and is willing to lead or co-invest and will seek a board seat when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A fully integrated healthcare solution provider headquartered in China is leading in several market segments in Asia, including family planning medicines, anesthesia, medicines for central nervous system, bio-medicines and others. The group is seeking in-licensing, acquisition, and partnership opportunities based in China and North America. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The group can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion.

The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the group is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The group seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.

The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The group typically seeks board representation after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A strategic corporate venture capital fund of an oncology pharmaceutical company seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the corporate’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the corporate’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in USA actively makes equity investments in early stage biotechnology companies with typical allocations of about $20-50M per company. The firm will consider investing in researchers located worldwide but typically create companies anywhere in the US where there is strong biology/biotech talent, inclusive but not limited to San Francisco, San Diego, Seattle, Dallas, NY, and Boston. The firm would only build/invest in a company elsewhere in exceptional circumstances.  The firm only considers opportunities in which they can participate in the first round of institutional investment.

The firm is seeking to build drug discovery and development companies, and prefers to invest at or before the preclinical stage; the firm is open to investing in concept-stage technologies that do not yet have protected IP.  The firm focuses on novel biology; the firm will consider investments in any disease area and is open to investing in any therapeutic technology provided the potential application of the technology has been established.  Only therapeutic technologies are of interest; devices and diagnostics will not be considered.

The firm typically engages prior to company formation.  The firm is a very hands-on investor and will take an active role in management recruitment and company-building.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.